Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06833073
PHASE2

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder. The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer. However, BCG may not work to treat HR NMIBC in some people. Researchers want to learn if adding intismeran autogene, the study treatment, to standard treatment can help treat HR NMIBC. Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study are to learn if people who receive V940 with BCG live longer and without the cancer growing, spreading, or coming back compared to people who receive BCG alone.

Official title: A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

308

Start Date

2025-03-11

Completion Date

2031-09-03

Last Updated

2026-04-06

Healthy Volunteers

No

Interventions

BIOLOGICAL

Intismeran autogene

IM injection

BIOLOGICAL

BCG

Intravesicular instillation. BCG is a preparation of Bacillus Calmette-Guerin.

Locations (89)

Michael G Oefelein Clinical Trials ( Site 0138)

Bakersfield, California, United States

Genesis Research, LLC ( Site 0141)

Los Alamitos, California, United States

USC Norris Comprehensive Cancer Center ( Site 0123)

Los Angeles, California, United States

Genesis Healthcare-Torrance ( Site 0140)

Torrance, California, United States

Genesis Research LLC ( Site 0118)

Torrance, California, United States

Urology Associates ( Site 0144)

Littleton, Colorado, United States

Urological Research Network ( Site 0133)

Hialeah, Florida, United States

Associated Urological Specialists - Chicago Ridge ( Site 0139)

Chicago Ridge, Illinois, United States

Southern Urology, LLC ( Site 0145)

Lafayette, Louisiana, United States

University of Missouri Health Care ( Site 0126)

Columbia, Missouri, United States

NHO Revive Research Institute, LLC ( Site 0137)

Lincoln, Nebraska, United States

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0111)

New York, New York, United States

TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122)

Cincinnati, Ohio, United States

OHSU Knight Cancer Institute - South Waterfront ( Site 0110)

Portland, Oregon, United States

MidLantic Urology ( Site 0102)

Bala-Cynwyd, Pennsylvania, United States

The Conrad Pearson Clinic ( Site 0143)

Germantown, Tennessee, United States

Texas Oncology-Austin Central ( Site 0107)

Austin, Texas, United States

Urology Austin, PLLC ( Site 0109)

Austin, Texas, United States

Urology of Virginia ( Site 0125)

Virginia Beach, Virginia, United States

University of Washington - Fred Hutchinson Cancer Center ( Site 0100)

Seattle, Washington, United States

Hospital Italiano de Buenos Aires ( Site 0307)

CABA, Buenos Aires, Argentina

Instituto Alexander Fleming ( Site 0306)

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Instituto de Investigaciones Clinicas Mar dle Plata ( Site 0305)

Mar del Plata, Buenos Aires, Argentina

Asociación de Beneficencia Hospital Sirio Libanés ( Site 0303)

Buenos Aires, Buenos Aires F.D., Argentina

Fundacion Estudios Clinicos ( Site 0304)

Rosario, Santa Fe Province, Argentina

Sanatorio Parque ( Site 0300)

Rosario, Santa Fe Province, Argentina

Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0301)

La Rioja, Argentina

Macquarie University ( Site 1801)

Macquarie University, New South Wales, Australia

Fiona Stanley Hospital ( Site 1803)

Perth, Western Australia, Australia

Instituto do Câncer e Transplante de Curitiba ( Site 0402)

Curitiba, Paraná, Brazil

Hospital de Clínicas de Passo Fundo ( Site 0406)

Passo Fundo, Rio Grande do Sul, Brazil

Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0400)

Barretos, São Paulo, Brazil

Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0410)

São Jose Do Rio Preto, São Paulo, Brazil

The Moncton Hospital-Oncology ( Site 0200)

Moncton, New Brunswick, Canada

CIUSSS de l'Estrie-CHUS ( Site 0204)

Sherbrooke, Quebec, Canada

Oncocentro Valdivia ( Site 0507)

Valdivia, Los Ríos Region, Chile

FALP ( Site 0500)

Santiago, Region M. de Santiago, Chile

Pontificia Universidad Catolica de Chile ( Site 0502)

Santiago, Region M. de Santiago, Chile

Bradfordhill ( Site 0501)

Santiago, Region M. de Santiago, Chile

ONCOCENTRO APYS ( Site 0505)

Viña del Mar, Región de Valparaíso, Chile

Bradford Hill Norte ( Site 0503)

Antofagasta, Chile

Instituto de Cancerología ( Site 0600)

Medellín, Antioquia, Colombia

Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0603)

Bogotá, Bogota D.C., Colombia

IMAT S.A.S ( Site 0601)

Montería, Departamento de Córdoba, Colombia

Oncólogos del Occidente S.A.S. - Sede Pereira ( Site 0604)

Pereira, Risaralda Department, Colombia

Clínica Imbanaco S.A.S ( Site 0602)

Cali, Valle del Cauca Department, Colombia

Herlev and Gentofte Hospital ( Site 3101)

Herlev, Capital Region, Denmark

CHU Dijon Bourgogne ( Site 0802)

Dijon, Cote-d Or, France

Bordeaux University Hospital - Pellegrin ( Site 0806)

Bordeaux, Gironde, France

CHU de Rouen- urology ( Site 0803)

Rouen, Haute-Normandie, France

Hôpital Foch-Urology department ( Site 0801)

Suresnes, Hauts-de-Seine, France

Hôpital Saint-Louis ( Site 0807)

Paris, Île-de-France Region, France

Klinikum Stuttgart - Katharinenhospital ( Site 0909)

Stuttgart, Baden-Wurttemberg, Germany

Klinikum der Universität München Großhadern ( Site 0910)

Munich, Bavaria, Germany

Marienhospital Herne ( Site 0907)

Herne, North Rhine-Westphalia, Germany

Universitaetsklinikum Halle ( Site 0902)

Halle, Saxony-Anhalt, Germany

Universitaetsklinikum Jena ( Site 0903)

Jena, Thuringia, Germany

Henry Dunant Hospital ( Site 1005)

Athens, Attica, Greece

Metropolitan General Hospital ( Site 1001)

Athens, Attica, Greece

ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1000)

Chaidari/Athens, Attica, Greece

European Interbalkan Medical Center-Oncology Department ( Site 1008)

Thessaloniki, Greece

Szegedi Tudomanyegyetem ( Site 1113)

Szeged, Csongrád megye, Hungary

Gyor- Moson- Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz ( Site 1116)

Győr, Győr-Moson-Sopron, Hungary

Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelőintézet ( Site 1118)

Eger, Heves County, Hungary

Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz Nyiregyhazi Josa Andras Tagkorhaza ( Site 1117)

Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary

Debreceni Egyetem Klinikai Kozpont ( Site 1112)

Debrecen, Hungary

Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1202)

Milan, Lombardy, Italy

Istituto Nazionale Tumori Regina Elena ( Site 1201)

Rome, Roma, Italy

Azienda USL 8 di Arezzo ( Site 1203)

Arezzo, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1200)

Roma, Italy

Rijnstate ( Site 1307)

Arnhem, Gelderland, Netherlands

Erasmus MC ( Site 1300)

Rotterdam, South Holland, Netherlands

Oncosalud ( Site 0701)

Lima, Lima Province, Peru

IPOR Instituto Peruano de Oncología & Radioterapia ( Site 0702)

San Isidro, Lima region, Peru

Hospital Militar Central Luis Arias Schereiber ( Site 0700)

Lima, Peru

Clinical Research Center Spółka z ograniczoną odpowiedzialnością MEDIC-R Sp.k ( Site 1402)

Poznan, Greater Poland Voivodeship, Poland

Szpital Wojewódzki im. Świętego Lukasza SP ZOZ w Tarnowie ( Site 1404)

Tarnów, Lesser Poland Voivodeship, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 1401)

Warszawa, Lesser Poland Voivodeship, Poland

Hospital Universitari Parc Tauli ( Site 1505)

Sabadell, Barcelona, Spain

Hospital Insular de Gran Canaria ( Site 1502)

Las Palmas de Gran Canaria, Canary Islands, Spain

Hospital Clinico San Carlos... ( Site 1500)

Madrid, Spain

Hospital Universitario 12 de Octubre ( Site 1507)

Madrid, Spain

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1506)

Madrid, Spain

Hospital Universitario Virgen Macarena ( Site 1504)

Seville, Spain

Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 3002)

Dusit, Bangkok, Thailand

Faculty of Medicine - Khon Kaen University ( Site 3001)

Muang, Changwat Khon Kaen, Thailand

Gartnavel General Hospital ( Site 1702)

Glasgow, Glasgow City, United Kingdom

St Bartholomew s Hospital ( Site 1700)

London, London, City of, United Kingdom

Torbay Hospital ( Site 1701)

Torquay, United Kingdom